QIAGEN Expands Bloodstream Infection Testing Menu in Europe with New AMR Panel — QIAGEN N.V.

Event summary

QIAGEN launched the CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel in Europe, expanding its bloodstream infection testing menu.
The new panel detects 13 gram-negative bacterial pathogen targets and 18 antimicrobial resistance (AMR) markers from positive blood cultures in about one hour.
Together with the previously launched QIAstat-Dx BCID GPF Plus AMR Panel, the two panels cover 33 pathogen targets and 28 AMR markers.
QIAGEN's QIAstat-Dx systems are available in over 100 countries with more than 5,200 instruments placed worldwide as of the end of 2025.

The big picture

QIAGEN's expansion of its bloodstream infection testing menu addresses a critical public health need amid rising antimicrobial resistance. The comprehensive coverage of gram-positive and gram-negative pathogens, along with key AMR markers, positions QIAGEN to support faster clinical decision-making and infection control. This strategic move aligns with the growing demand for rapid, accurate diagnostic solutions in infectious disease management.

What we're watching

Regulatory Progress: Whether the U.S. FDA will approve the panel, expanding its market reach beyond Europe.
Market Adoption: The pace at which hospitals and laboratories adopt the expanded QIAstat-Dx menu for comprehensive bloodstream infection testing.
Competitive Positioning: How QIAGEN's rapid, cartridge-based molecular testing will differentiate it from competitors in the syndromic testing space.